Esperion Therapeutics Inc. stocks have been trading up by 55.0 percent following highly positive coverage of its cholesterol drug.
Click Here for a Millionaire's POV on Trading ESPR
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- ARCHIMED will acquire Esperion for $3.16 per share in cash plus a non‑tradeable CVR tied to future sales, valuing the deal at up to about $1.1B and leading to a planned Nasdaq delisting in Q3 2026.
- The $3.16 per share cash offer represents a 58% premium to the prior close, with up to $100M in extra milestone payments tied to NEXLETOL/NEXLIZET and ENBUMYST.
- Jefferies cut its rating to Hold and trimmed its price target to $3.28 after the deal, flagging competitive pressure over the next 6–18 months and limited upside beyond the offer.
- Multiple shareholder-rights law firms, including Halper Sadeh LLC and Ademi LLP, are reviewing whether the ARCHIMED terms are fair and if the board handled conflicts and disclosures properly.
- Q1 2026 results are due 2026/05/07, with management set to update traders on cardiometabolic products and the pipeline that backstop the CVR value.
Weekly Update Apr 27 – May 01, 2026: On Sunday, May 03, 2026 Esperion Therapeutics Inc. stock [NASDAQ: ESPR] is trending up by 55.0%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – neutral
Esperion Therapeutics sits in a niche cardiometabolic space with an increasingly credible commercial profile but a structurally weak balance sheet. Revenue growth is strong (three‑year CAGR ~75%) with unusually high reported gross margin (125%) and solid EBIT margin (~16%), confirming real operating leverage from the NEXLETOL/NEXLIZET franchise. However, deeply negative ROA, large accumulated deficits, negative equity, and high interest burden (coverage only ~0.8x) underscore dependence on external capital and justify a modest 2.0x sales valuation.
Technically, ESPR’s dominant near‑term driver is the announced ARCHIMED takeout, not fundamentals. The stock gapped from roughly $2.00 to above $3.00, with the recent weekly close at $3.10, aligning tightly with the $3.16 cash bid and leaving limited arbitrage spread. Price action and intraday 5‑minute candles show consolidation with declining incremental volume, consistent with a merger‑arb regime. The key actionable trading level is $3.00 support; sustained trade below $2.80 would signal rising deal‑break risk.
More Breaking News
- RNTX Stock Dips As Traders Weigh Deep Losses And Cash Runway
- CMPX Stock Plunges As Traders Weigh Cancer Trial Fallout
- RDDT Stock Draws Bullish Call As Volatility And Regulation Loom
- TWO Surges As UWM Tops CrossCountry Mortgage Buyout Deal
The acquisition by ARCHIMED at $3.16 plus a non‑tradable CVR effectively caps upside versus healthcare and pharma benchmarks, which retain open‑ended growth. Legal investigations into deal fairness may influence timing but are unlikely to unlock substantially higher headline consideration. With privatization and Nasdaq delisting expected in Q3 2026, ESPR now trades as a yield‑to‑close arbitrage play. Base‑case fair value is $3.05–$3.20 with resistance at $3.20 and negligible strategic merit beyond deal‑risk sizing.
Quick Financial Overview
ESPR’s chart shows how quickly deal news can reset price. The stock moved from a prior close under $2 to a post-deal open around $3.11–$3.13, almost exactly in line with the $3.16 cash offer. That is a clean gap-up and re-pricing, with the weekly candles showing a sharp jump from the $1.90–$2.01 zone straight into the low-$3s, where price is now pinned by the takeover terms.
On the intraday tape, Esperion Therapeutics Inc. is trading in a very tight band between $3.10 and $3.14. That kind of narrow range near the offer price is textbook merger-arb behavior, not momentum trading. For active traders, ESPR has essentially shifted from a breakout or trend setup into a spread-trading situation where the main question is whether the deal closes as announced.
Under the hood, ESPR’s fundamentals explain why a private equity buyer like ARCHIMED stepped in. The company printed about $403.1M in revenue, with strong gross margin of 125.2% and an EBIT margin of 15.8%, but bottom-line profit margin for continuing operations is still negative at -5.63%. Cash flow is healthier: operating cash flow of $45.24M and end cash of $167.85M give some runway, while an enterprise value near $884.9M and price-to-sales around 1.99 show the takeout is not being done at a bargain-basement multiple. Debt remains meaningful, with long-term debt at roughly $250.13M and interest coverage at only 0.8, which keeps financial risk on the table.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.